Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers

Table 1

Outcomes of affected BRCA1/2 mutation carriers.

Study	Design	Patients	Followup	IBTR	BCSS	OS
Pierce et al. [40]	1	BCT = 302; Mast. = 353	8.2 to 8.9 years. Data projected to 15 years	BCT = 23.5%; Mast. = 5.5%	BCT = 91.7%; Mast. = 92.8%; 𝑃=0.85	BCT = 87.3%; Mast. = 89.8%; 𝑃=0.73
Haffty et al. [22]	2	BRCA = 22; Sporadic = 105	12.7 years	BRCA = 41%; Sporadic = 19%; 𝑃=0.007
Garcia-Etiene et al. [23]	3	BRCA = 54; Sporadic = 162	4 years. Data projected to 10 years	BRCA = 27%; Sporadic = 4%; 𝑃=0.03
Pierce et al. [21]	4	BRCA = 160; Sporadic = 445	6.7 to 7.9 years. Data projected to 15 years	BRCA = 24%; Sporadic = 17%; 𝑃=0.19
Kirova et al. [20]	5	BRCA = 27; Familial = 104; Sporadic = 261	13.4 years	BRCA = 45%; Familial = 31%; Sporadic = 24%; 𝑃=0.33		Not significant at 20 years. Actual rates not reported.
Brekelmans et al. [25]	6	BRCA = 326; Familial = 311; Sporadic = 759	4.3 to 5.1 years. Data projected to 10 years	BRCA = 20 to 25%; Familial = 6%; Sporadic = 5%; 𝑃=0.001	BRCA = 62 to 68%; Familial = 70%; Sporadic = 59%; 𝑃=0.17	BRCA = 50 to 60%; Familial = 66%; Sporadic = 55%; 𝑃=0.32
Robson et al. [41]	7	BRCA = 28; Sporadic = 277	10.3 years	BRCA = 22%; Sporadic = 7%; 𝑃=0.25	BRCA = 72%; Sporadic = 87%; 𝑃=0.02*	BRCA = 66%; Sporadic = 81%; 𝑃=0.05*
Robson et al. [19]	8	BRCA = 56; Sporadic = 440	9.7 years		BRCA1 = 63%; BRCA2 = 86%; Sporadic = 86%; 𝑃=<0.0001**

Abbreviations: IBTR: in-breast tumor recurrence; BCSS: breast cancer-specific survival; OS: overall survival; BCT: breast conserving therapy; Mast.: mastectomy; BRCA: BRCA1/2 unless otherwise specified.
Study design: 1, BRCA1/2 carriers diagnosed with breast cancer treated with BCT or mastectomy. 2, BRCA1/2 carriers versus sporadic cancer diagnosis in women <42 years of age undergoing BCT. 3, BRCA1/2-associated cancer matched with sporadic controls for age and year of surgery treated with BCT. 4, BRCA1/2-associated cancer matched with sporadic controls treated with BCT. 5, BRCA1/2-associated cancer versus patients with family history of breast or ovarian cancer versus sporadic controls matched for age and year of diagnosis treated with BCT. 6, breast cancer patients with versus without a family history of BRCA1/2 mutation versus sporadic controls matched for age and year of diagnosis treated with BCT or mastectomy. 7, Ashkenazi Jewish women with versus without the BRCA1/2 founder mutation undergoing BCT. 8, Ashkenazi Jewish women with versus without the BRCA1/2 founder mutation undergoing BCT.
*Reached significance on univariate analysis but was lost on multivariate analysis.
**This result was mitigated by and was no longer significant after the addition of chemotherapy.